India cuts approval timelines

India’s drug regulator has cut several approval timelines by more than half, speeding up how quickly companies can move new medicines into trials and toward the market. (economictimes.indiatimes.com) The Central Drugs Standard Control Organisation, India’s national drug regulator, is now clearing clinical-trial applications in about 120 to 135 days and marketing authorisations in under 150 days, according to The Economic Times report published on April 14, 2026. (economictimes.indiatimes.com) The changes build on amendments the Union Health Ministry notified on January 28, 2026 to the New Drugs and Clinical Trials Rules, 2019. Those amendments replaced some test-licence requirements for non-commercial manufacture with an online prior-intimation system and cut the statutory processing period for remaining test licences to 45 days from 90 days. (pib.gov.in) The ministry said the prior-intimation route does not apply to a narrower set of higher-risk products, including cytotoxic drugs, narcotic drugs and psychotropic substances. It also waived prior permission for specified low-risk bioavailability and bioequivalence studies, which are studies used to show a generic medicine behaves in the body like the original product. (pib.gov.in) India’s current drug-approval system sits on the New Drugs and Clinical Trials Rules, 2019, which govern clinical trials, bioavailability studies and approvals for new drugs under the Drugs and Cosmetics Act, 1940. The 2026 amendments are the biggest procedural rewrite to that framework since the rules were introduced in March 2019. (cdsco.gov.in, economictimes.indiatimes.com) The government said the January amendments alone should shave at least 90 days off drug-development timelines. It also said the regulator handles about 30,000 to 35,000 test-licence applications a year and roughly 4,000 to 4,500 bioavailability and bioequivalence study applications annually. (pib.gov.in) That matters in a country whose pharmaceutical sector is one of the world’s largest by volume and a major exporter of generic medicines. The Press Information Bureau said in December 2025 that India’s pharmaceutical exports reached $30.47 billion in 2024-25, up 9.4% from the previous year. (pib.gov.in, pib.gov.in) The January notification framed the overhaul as part of a wider “ease of doing business” push under Prime Minister Narendra Modi’s government. The Economic Times report on April 14 said the regulator has also removed some pre-clinical approval requirements, extending that effort beyond the test-licence changes announced in January. (pib.gov.in, economictimes.indiatimes.com) The practical effect is that Indian drugmakers can start some early regulatory steps with an online filing instead of waiting months for formal permission, while full reviews for trials and market approvals are also moving faster. For companies racing to launch generics or develop new products, the bottleneck has shifted from paperwork to how quickly they can generate data the regulator will accept. (economictimes.indiatimes.com, economictimes.indiatimes.com)